JP2005522999A - 癌を処置するための方法および組成物 - Google Patents

癌を処置するための方法および組成物 Download PDF

Info

Publication number
JP2005522999A
JP2005522999A JP2003564555A JP2003564555A JP2005522999A JP 2005522999 A JP2005522999 A JP 2005522999A JP 2003564555 A JP2003564555 A JP 2003564555A JP 2003564555 A JP2003564555 A JP 2003564555A JP 2005522999 A JP2005522999 A JP 2005522999A
Authority
JP
Japan
Prior art keywords
protein
activity
expression
mrna
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003564555A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005522999A5 (enExample
Inventor
ジョン ジョセフ ハンター，
カイル ジェイ． マクベス，
フォン−イン ツァイ，
アンドレア レスーン，
エリック エス． ライトキャップ，
マーク ダブリュー． ウィリアムソン，
ローラ エー． ルドルフ−オーウェン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of JP2005522999A publication Critical patent/JP2005522999A/ja
Publication of JP2005522999A5 publication Critical patent/JP2005522999A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2003564555A 2002-01-31 2003-01-30 癌を処置するための方法および組成物 Pending JP2005522999A (ja)

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
US35360002P 2002-01-31 2002-01-31
US36451702P 2002-03-15 2002-03-15
US37107502P 2002-04-09 2002-04-09
US37150702P 2002-04-10 2002-04-10
US37298402P 2002-04-16 2002-04-16
US37419402P 2002-04-19 2002-04-19
US38299502P 2002-05-24 2002-05-24
US38502302P 2002-05-31 2002-05-31
US38885302P 2002-06-14 2002-06-14
US38939502P 2002-06-17 2002-06-17
US39132402P 2002-06-25 2002-06-25
US39594402P 2002-07-15 2002-07-15
US39772602P 2002-07-22 2002-07-22
US40304602P 2002-08-13 2002-08-13
US40515502P 2002-08-22 2002-08-22
US40636102P 2002-08-27 2002-08-27
US42119502P 2002-10-25 2002-10-25
US42545602P 2002-11-12 2002-11-12
US42762602P 2002-11-19 2002-11-19
US43212202P 2002-12-10 2002-12-10
PCT/US2003/002588 WO2003065006A2 (en) 2002-01-31 2003-01-30 Methods and compositions for treating cancer

Publications (2)

Publication Number Publication Date
JP2005522999A true JP2005522999A (ja) 2005-08-04
JP2005522999A5 JP2005522999A5 (enExample) 2006-03-02

Family

ID=27671411

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003564555A Pending JP2005522999A (ja) 2002-01-31 2003-01-30 癌を処置するための方法および組成物

Country Status (5)

Country Link
US (2) US20030157082A1 (enExample)
EP (1) EP1468118A4 (enExample)
JP (1) JP2005522999A (enExample)
AU (1) AU2003225535A1 (enExample)
WO (1) WO2003065006A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005537810A (ja) * 2002-09-11 2005-12-15 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
US8871719B2 (en) 2010-01-25 2014-10-28 Oncotherapy Science, Inc. Modified MELK peptides and vaccines containing the same

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004537291A (ja) * 2001-05-24 2004-12-16 セフアロン・インコーポレーテツド 新規混合系統キナーゼ（７）（ｍｌｋ７）ポリペプチド、それをコードするポリヌクレオチド、およびそれらの使用方法
WO2002102323A2 (en) 2001-06-14 2002-12-27 Bristol-Myers Squibb Company Novel human histone deacetylases
US20030153018A1 (en) * 2001-11-27 2003-08-14 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cancer using 2192, 2193, 6568, 8895, 9138, 9217, 9609, 9857, 9882, 10025, 20657, 21163, 25848, 25968, 32603, 32670, 33794, 54476 and 94710
US20030199462A1 (en) * 2002-04-23 2003-10-23 Gabriel Nunez Methods and compositions for regulating cellular signaling
EP1431399A1 (en) * 2002-12-20 2004-06-23 Clinigenetics Methods and composition for identifying therapeutic agents of atherosclerotic plaque lesions
WO2005103255A1 (en) * 2004-03-25 2005-11-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Formylpeptide receptor (fpr) as a target for anti-malignant glioma therapy
EP2256198A1 (en) * 2004-06-14 2010-12-01 Galapagos N.V. Methods for identification, and compounds useful for the treatment of degenerative and inflammatory diseases
CN101068935B (zh) * 2004-08-10 2012-06-27 肿瘤疗法科学股份有限公司 与乳腺癌相关的基因和多肽
CA2637988A1 (en) 2006-02-10 2007-11-29 Genentech, Inc. Anti-fgf19 antibodies and methods using same
US8148338B2 (en) * 2006-02-22 2012-04-03 Supratek Pharma Inc. Doxorubicin formulations for anti-cancer use
JP2010511382A (ja) * 2006-12-01 2010-04-15 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 癌関連タンパク質キナーゼ
EP2188310B1 (en) 2007-08-03 2017-02-08 Genentech, Inc. Humanized anti-fgf19 antagonists and methods using same
WO2012037553A2 (en) * 2010-09-17 2012-03-22 University Of South Florida Use of pkc-iota inhibitors for the treatment of breast cancer
EP2060583A1 (en) * 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
AU2016201637B2 (en) * 2007-10-23 2017-05-25 Biontech Ag Identification of tumor-associated markers for diagnosis and therapy
EP2245066A2 (en) * 2008-01-22 2010-11-03 Biogen Idec MA Inc. Ron antibodies and uses thereof
TWI466680B (zh) 2008-08-01 2015-01-01 Oncotherapy Science Inc Ｍｅｌｋ抗原決定位胜肽及含此胜肽的疫苗
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
US8632982B2 (en) * 2009-05-21 2014-01-21 Institute For Systems Biology Biomarkers for liver injury
WO2010141349A1 (en) * 2009-05-30 2010-12-09 University Of Toledo Soluble guanylyl cyclase a1 and a-8r peptide as diagnostic markers of and therapeutic targets for prostate cancer
US9301991B2 (en) 2009-05-30 2016-04-05 The University Of Toledo sGCalphal inhibiting compositions
DK3345615T3 (da) 2010-03-01 2020-01-20 Bayer Healthcare Llc Optimerede monoklonale antistoffer mod inhibitor af vævsfaktoraktiveringsvejen (tfpi)
US20150018294A1 (en) * 2012-02-07 2015-01-15 Arrigo DE BENEDETTI Modulators of tousled kinase in cellular processes
US11058767B2 (en) 2018-02-21 2021-07-13 Bristol-Myers Squibb Company CAMK2D antisense oligonucleotides and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3395900A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
KR20020093017A (ko) * 2000-04-03 2002-12-12 상꾜 가부시키가이샤 포유동물 스핑고신 키나제 유형 2 이성체, 이의 클로닝,발현 및 사용 방법
JP2003532057A (ja) * 2000-04-07 2003-10-28 アリーナ・フアーマシユーチカルズ・インコーポレーテツド 非内因性の、構成的に活性化される既知ｇタンパク質−共役受容体
EP1578996A4 (en) * 2002-10-18 2007-12-19 Genentech Inc COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING TUMORS

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005537810A (ja) * 2002-09-11 2005-12-15 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
US8871719B2 (en) 2010-01-25 2014-10-28 Oncotherapy Science, Inc. Modified MELK peptides and vaccines containing the same

Also Published As

Publication number Publication date
US20030157082A1 (en) 2003-08-21
WO2003065006A3 (en) 2004-04-08
EP1468118A2 (en) 2004-10-20
AU2003225535A1 (en) 2003-09-02
US20070078088A1 (en) 2007-04-05
WO2003065006A2 (en) 2003-08-07
EP1468118A4 (en) 2006-08-02

Similar Documents

Publication Publication Date Title
JP2005522999A (ja) 癌を処置するための方法および組成物
US20040235071A1 (en) Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476, 62113, 64316, 12264, 32362, 58198, 2887, 3205, 8557, 9600, 9693, 44867, 53058, 55556, 57658, 2208, 10252, 10302, 14218, 33877, 10317, 10485, 25964, 14815, 1363, 1397, 14827, 21708, 3801, 64698, 2179 or 13249
JP2007520996A (ja) ４４３９０、５４１８１、２１１、５６８７、８８４、１４０５、６３６、４４２１、５４１０、３０９０５、２０４５、１６４０５、１８５６０、２０４７、３３７５１、５２８７２、１４０６３、２０７３９、３２５４４、４３２３９、４４３７３、５１１６４、５３０１０、１６８５２、１５８７、２２０７、２２２４５、２３８７、５２９０８、６９１１２、１４９９０、１８５４７、１１５、５７９、１５９８５、１５６２５、７６０、１８６０３、２３９５、２５５４、８６７５、３２７２０、４８０９、１４３０３、１６８１６、１７８２７、３２６２０、５７７、６１９、１４２３、２１５８、８２６３、１５４０２、１６２０９、１６３８６、２１１６５、３０９１１、４１８９７、１６４３、２５４３、９６２６、１３２３１、３２４０９、８４２６０、２８８２、８２０３、３２６７８または５５０５３を用いて泌尿器科障害を処置するための方法および組成物
US20040091929A1 (en) Methods and compositions for the diagnosis and treatment of cardiovascular and tumorigenic disease using 4941
US20030152574A1 (en) Methods and compositions to treat cardiovascular disease using 1419, 58765 and 2210
JP2005525112A (ja) ジアシルグリセロールキナーゼεを使用して疼痛を処置する際の方法および組成物
US20030108937A1 (en) Methods and compositions for the diagnosis and treatment of cellular proliferation disorders using 20750
US7037668B2 (en) Methods for the treatment and diagnosis of tumorigenic and angiogenic disorders using 32616
US20030148394A1 (en) Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058, or 6351 molecules
HUP0303905A2 (hu) KIAA-nukleinsavak és -polipeptidek prosztatarák diagnosztizálására és gyógykezelésére alkalmas expressziós analízise
JP2005513422A (ja) 癌を処置するための方法および組成物
US20030119742A1 (en) Methods and compositions to treat cardiovascular disease using 139, 258, 1261, 1486, 2398, 2414, 7660, 8587,10183, 10550, 12680, 17921, 32248, 60489 or 93804
US20030104455A1 (en) Methods and compositions for treating urological disorders using 313, 333, 5464, 18817 or 33524
US20030124593A1 (en) Methods and compositions for the treatment and diagnosis of cellular proliferation disorders using 25943
US20030113777A1 (en) Methods and compositions for the treatment and diagnosis of cellular proliferative disorders using 32222
EP1463832A2 (en) Methods and compositions for the diagnosis and treatment of cellular proliferation disorders using 86604

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081111

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090515